ToBeSoft Presents Research Results on Combination Cancer Therapy at AACR of the American Association for Cancer Research

[Asia Economy Reporter Hyunseok Yoo] ToBeSoft announced on the 26th that it will participate in the '2020 American Association for Cancer Research (AACR) Annual Meeting' held in San Diego, USA, in April and present a poster.

AACR is one of the top three cancer societies in the United States, with 40,000 members worldwide. Every year, more than 20,000 researchers gather to share clinical results on cancer, introduce innovative technologies, and discuss the latest trends in cancer treatment. At AACR, ToBeSoft plans to present preclinical efficacy test results of a new drug candidate being repositioned as an anticancer combination therapy.

Through its subsidiary ToBeBioNewDrug, ToBeSoft is developing immuno-oncology drugs based on Alloferon and Allostatine. Alloferon is a substance prescribed over one million times in Russia, verifying its safety, and Allostatine is a new drug candidate that enhances the anticancer effects of Alloferon. Both substances have excellent immune-enhancing effects and are being developed as treatments through combination prescriptions with existing anticancer drugs.

A ToBeSoft official stated, "This AACR presentation by ToBeBioNewDrug signifies that the repositioning of antiviral drugs into anticancer drugs is progressing smoothly."

He added, "Both Alloferon and Allostatine activate NK cells that directly destroy virus-infected cells, strengthening the immune system, so we believe these substances can also be effective against viral diseases such as the current COVID-19. We expect to announce meaningful research results on indication expansion this year."

This content was produced with the assistance of AI translation services.